Biliary atresia is a rare, but one of the most common severe pediatric liver diseases affecting approximately 1:5000 to 1:18,000 newborns. Recent intervention studies on immune modulation for biliary atresia have not yielded any substantial improvement in altering the liver disease trajectory and associated liver disease related complications. As such, biliary atresia continues to account for approximately 40-50% of pediatric liver transplantations in the United States.
The purpose of this meeting will be to bring together clinical and translational experts in biliary atresia to examine the current state of clinical and translational science that will allow for the identification and prioritization of achievable and feasible research priorities that will further advance the understanding of the clinical pathophysiology of this condition.
Further details regarding the agenda, date and location of this meeting will be forthcoming on this website.
Ronald Sokol, M.D., University of Colorado School of Medicine
Rebecca Wells, M.D., University of Pennsylvania School of Medicine
Jorge Bezera, M.D., Cincinnati Children's Hospital Medical Center
Edward Doo, M.D., NIDDK/NIH
Jay Hoofnagle, M.D., NIDDK/NIH
June 1, 2017 or until full.
RSVP to Lauren Meskill via email with your name, affiliation and phone number.